In September 2024, Yocon's mesenchymal stem cell serum-free medium obtained the US FDA 510(K) Class II medical device registration certificate, becoming the second globally and the first in China to obtain such a certificate, significantly enhancing the international influence of domestic serum-free medium products.
In the field of molecular diagnostics, Yocon focuses on viral sampling products and molecular detection products for quality control. Yocon's viral sampling products are rare Class II medical device registered products in China, have successfully passed product tests in multiple countries in Europe, America, and Southeast Asia, are exported to over 30 countries and regions, and have been designated by governments in Canada, Australia, and other countries.
In 2020, Yocon invested 250 million to construct a 42,000-square-meter intelligent R&D and production base in Miyun District, Beijing, which fully commenced production in May 2024. The production environment of this base meets the regulatory requirements of the National Medical Products Administration (NMPA) of China, CE, and FDA, perfectly supporting customers' hardware requirements for drug submissions and production in China and the United States.
On its new journey, Yocon will more closely meet user needs, provide more high-quality and innovative products to customers both domestically and internationally, continuously pursue excellence, and use its hands to usher in a new era in the field of cell therapy.
